Oral TXNIP Inhibitor TIX100 Enters Multiple-Dose Trial, Initially Assessing Safety and Pharmacokinetics in 18 Participants

Treatment for type 1 diabetes has long centered on insulin supplementation, but if the loss of patients’ own pancreatic beta cells could be delayed, disease management might not have to focus solely on lowering blood glucose. U.S. pharmaceutical startup TIXiMED is pursuing this approach with the oral drug candidate TIX100. Its newly launched Phase 1 multiple-dose trial will first determine whether the drug can maintain acceptable safety and pharmacokinetic profiles during continuous dosing.

Clinical trial registry data show that this randomized, double-blind, placebo-controlled study, identified as NCT07675590, is expected to enroll 18 adults who are overweight or obese but otherwise healthy. Participants will be assigned to three ascending-dose groups and receive TIX100 or placebo twice daily for 28 consecutive days, followed by seven days of follow-up. The primary measures include adverse events, tolerability, and how the drug is absorbed and cleared in the body.

TIX100 targets thioredoxin-interacting protein, or TXNIP. Levels of this metabolic regulatory protein increase in high-glucose environments, and research suggests that it is associated with pancreatic islet cell stress, beta-cell death, glucagon secretion, and hepatic glucose production. By inhibiting TXNIP expression, TIXiMED hopes to preserve the body’s ability to produce its own insulin and ultimately position the drug as an adjunctive therapy alongside insulin, rather than a replacement for insulin.

The company previously completed a single ascending-dose trial involving 28 healthy adults and said that no drug-related adverse events, electrocardiogram changes, or hypoglycemia occurred in any dose group. In a post hoc analysis, the company also observed a smaller rise in blood glucose after a standard meal in the high-dose group. However, this was not a prespecified efficacy outcome and has not yet undergone full peer review. Given the small sample and the fact that participants did not have diabetes, it can only be regarded as an early, hypothesis-generating signal.

As the clinical program advances, TIXiMED has also appointed CEO Stephen E. Daly and Albert R. Collinson to its board of directors. Daly has worked at several companies focused on diabetes and metabolic diseases, while Collinson has experience advancing an SGLT2 inhibitor through development and U.S. approval. These appointments may strengthen the company’s fundraising, development, and commercialization capabilities, but they do not constitute scientific evidence that TIX100 is effective or safe.

The crucial tests still lie ahead: this trial has a limited number of participants, and its subjects do not have type 1 diabetes, so it cannot determine whether TIX100 can preserve beta-cell function, reduce insulin requirements, or improve long-term glycemic control. If the multiple-dose safety data support continued development, the company plans to conduct a Phase 2 proof-of-concept study next in patients newly diagnosed with type 1 diabetes. Until randomized, controlled patient data are obtained, “disease modification” remains a development objective that has yet to be validated.